Madrigal (MDGL) Rule 144 Notice: 2,000 Shares Via Morgan Stanley
Rhea-AI Filing Summary
Madrigal Pharmaceuticals (MDGL) Form 144 filing shows a proposed sale of 2,000 common shares to be executed through Morgan Stanley Smith Barney on 08/18/2025 with an aggregate market value of $764,481.20. The filer states these 2,000 shares were acquired the same day by exercise of options under a registered plan and paid in cash. The filing also discloses that the same person sold 4,100 shares on 08/15/2025 for gross proceeds of $1,503,481.48. The filer signs a representation that they are unaware of any undisclosed material adverse information about the issuer.
Positive
- Full Rule 144 disclosure provided with broker, quantities, prices, acquisition method, and prior three-month sales
- Acquisition method disclosed as exercise of options under a registered plan and sale consideration specified as cash
- Filer attestation that they do not possess undisclosed material adverse information
Negative
- Insider sales disclosed: 4,100 shares sold on 08/15/2025 and 2,000 shares proposed for sale on 08/18/2025, which may concern some investors
- No issuer operating or financial details are included in the filing, so it does not provide context for the transactions
Insights
TL;DR: Routine insider sale following option exercise; disclosure complies with Rule 144 requirements.
The filing documents a planned sale of 2,000 common shares of Madrigal acquired by exercise of options on the same date and to be sold through Morgan Stanley Smith Barney on 08/18/2025 for an aggregate market value of $764,481.20. The filer also reported a recent sale of 4,100 shares on 08/15/2025 generating $1,503,481.48. This is a straightforward Rule 144 notice that provides required transaction timing, consideration (cash), and broker details. No earnings or other issuer-specific operating data are included in the filing.
TL;DR: Disclosure is complete for Rule 144 purposes and includes the seller's attestation about material nonpublic information.
The document supplies the necessary specifics: class of security, broker name and address, number of shares to be sold, aggregate market value, outstanding shares, acquisition date and method (exercise of options), and prior sales in the last three months. The filer affirms no knowledge of undisclosed material adverse information and highlights compliance with Rule 144 procedures. The filing does not provide issuer financials or context beyond transaction-level details.